fda warning letters compounding semaglutide september 2025 The sent a letter this month to Novo Nordisk, alleging the drugmaker failed to report, in a timely manner, potential side effects in patients who took its popular medications containing FDA Sends Warning Letters to

The same year, tirzepatide gained a lot of attention after a study was published in The New England Journal of Medicine [6] that demonstrated its superior effect on weight loss compared to semaglutide in patients with type 2 diabetes, along with greater reduction in HbA1c levels

These alternatives may appeal to patients seeking affordability or access during shortages, although they operate in a regulatory gray zone that is drawing increasing scrutiny from the FDA

Accessed 6/23/2025, Lee YJ, Lee JY, Cho JH, Kang YJ, Choi JH

Key Points for Practice All adults should be tested for diabetes beginning at 45 years of age

Astaxanthin inhibits mitochondrial dysfunction and interleukin-8 expression in Helicobacter pylori -infected gastric epithelial cells